Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Lipodystrophies are rare, heterogeneous, genetic or acquired, disorders characterised by varying degrees of body fat loss and associated metabolic complications, including insulin resistance, dyslipidaemias, hepatic steatosis and predisposition to atherosclerotic cardiovascular disease (ASCVD). The four main types of lipodystrophy, excluding antiretroviral therapy-induced lipodystrophy in HIV-infected patients, are congenital generalised lipodystrophy (CGL), familial partial lipodystrophy (FPLD), acquired generalised lipodystrophy (AGL) and acquired partial lipodystrophy (APL). This paper reviews the literature related to the prevalence of dyslipidaemias and ASCVD in patients with lipodystrophies. Patients with CGL, AGL and FPLD have increased prevalence of dyslipidaemia but those with APL do not. Patients with CGL as well as AGL present in childhood, and have severe dyslipidaemias (mainly hypertriglyceridaemia) and early onset diabetes mellitus as a consequence of extreme fat loss. However, only a few patients with CGL and AGL have been reported to develop coronary heart disease. In contrast, data from some small cohorts of FPLD patients reveal increased prevalence of ASCVD especially among women. Patients with APL have a relatively low prevalence of hypertriglyceridaemia and diabetes mellitus. Overall, patients with lipodystrophies appear to be at high risk of ASCVD due to increased prevalence of dyslipidaemia and diabetes and efforts should be made to manage these metabolic complications aggressively to prevent ASCVD.

Original languageEnglish (US)
JournalPathology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Congenital Generalized Lipodystrophy
Lipodystrophy
Dyslipidemias
Cardiovascular Diseases
Familial Partial Lipodystrophy
Hypertriglyceridemia
Diabetes Mellitus
Coronary Disease
Insulin Resistance
Adipose Tissue
Fats
HIV

Keywords

  • acquired generalised lipodystrophy
  • acquired partial lipodystrophy
  • congenital generalised lipodystrophy
  • familial partial lipodystrophy
  • Lipodystrophy
  • metreleptin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{d7d744eeaa834e68b5cd0bc0e006ca5b,
title = "Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease",
abstract = "Lipodystrophies are rare, heterogeneous, genetic or acquired, disorders characterised by varying degrees of body fat loss and associated metabolic complications, including insulin resistance, dyslipidaemias, hepatic steatosis and predisposition to atherosclerotic cardiovascular disease (ASCVD). The four main types of lipodystrophy, excluding antiretroviral therapy-induced lipodystrophy in HIV-infected patients, are congenital generalised lipodystrophy (CGL), familial partial lipodystrophy (FPLD), acquired generalised lipodystrophy (AGL) and acquired partial lipodystrophy (APL). This paper reviews the literature related to the prevalence of dyslipidaemias and ASCVD in patients with lipodystrophies. Patients with CGL, AGL and FPLD have increased prevalence of dyslipidaemia but those with APL do not. Patients with CGL as well as AGL present in childhood, and have severe dyslipidaemias (mainly hypertriglyceridaemia) and early onset diabetes mellitus as a consequence of extreme fat loss. However, only a few patients with CGL and AGL have been reported to develop coronary heart disease. In contrast, data from some small cohorts of FPLD patients reveal increased prevalence of ASCVD especially among women. Patients with APL have a relatively low prevalence of hypertriglyceridaemia and diabetes mellitus. Overall, patients with lipodystrophies appear to be at high risk of ASCVD due to increased prevalence of dyslipidaemia and diabetes and efforts should be made to manage these metabolic complications aggressively to prevent ASCVD.",
keywords = "acquired generalised lipodystrophy, acquired partial lipodystrophy, congenital generalised lipodystrophy, familial partial lipodystrophy, Lipodystrophy, metreleptin",
author = "Iram Hussain and Nivedita Patni and Abhimanyu Garg",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.pathol.2018.11.004",
language = "English (US)",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease

AU - Hussain, Iram

AU - Patni, Nivedita

AU - Garg, Abhimanyu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Lipodystrophies are rare, heterogeneous, genetic or acquired, disorders characterised by varying degrees of body fat loss and associated metabolic complications, including insulin resistance, dyslipidaemias, hepatic steatosis and predisposition to atherosclerotic cardiovascular disease (ASCVD). The four main types of lipodystrophy, excluding antiretroviral therapy-induced lipodystrophy in HIV-infected patients, are congenital generalised lipodystrophy (CGL), familial partial lipodystrophy (FPLD), acquired generalised lipodystrophy (AGL) and acquired partial lipodystrophy (APL). This paper reviews the literature related to the prevalence of dyslipidaemias and ASCVD in patients with lipodystrophies. Patients with CGL, AGL and FPLD have increased prevalence of dyslipidaemia but those with APL do not. Patients with CGL as well as AGL present in childhood, and have severe dyslipidaemias (mainly hypertriglyceridaemia) and early onset diabetes mellitus as a consequence of extreme fat loss. However, only a few patients with CGL and AGL have been reported to develop coronary heart disease. In contrast, data from some small cohorts of FPLD patients reveal increased prevalence of ASCVD especially among women. Patients with APL have a relatively low prevalence of hypertriglyceridaemia and diabetes mellitus. Overall, patients with lipodystrophies appear to be at high risk of ASCVD due to increased prevalence of dyslipidaemia and diabetes and efforts should be made to manage these metabolic complications aggressively to prevent ASCVD.

AB - Lipodystrophies are rare, heterogeneous, genetic or acquired, disorders characterised by varying degrees of body fat loss and associated metabolic complications, including insulin resistance, dyslipidaemias, hepatic steatosis and predisposition to atherosclerotic cardiovascular disease (ASCVD). The four main types of lipodystrophy, excluding antiretroviral therapy-induced lipodystrophy in HIV-infected patients, are congenital generalised lipodystrophy (CGL), familial partial lipodystrophy (FPLD), acquired generalised lipodystrophy (AGL) and acquired partial lipodystrophy (APL). This paper reviews the literature related to the prevalence of dyslipidaemias and ASCVD in patients with lipodystrophies. Patients with CGL, AGL and FPLD have increased prevalence of dyslipidaemia but those with APL do not. Patients with CGL as well as AGL present in childhood, and have severe dyslipidaemias (mainly hypertriglyceridaemia) and early onset diabetes mellitus as a consequence of extreme fat loss. However, only a few patients with CGL and AGL have been reported to develop coronary heart disease. In contrast, data from some small cohorts of FPLD patients reveal increased prevalence of ASCVD especially among women. Patients with APL have a relatively low prevalence of hypertriglyceridaemia and diabetes mellitus. Overall, patients with lipodystrophies appear to be at high risk of ASCVD due to increased prevalence of dyslipidaemia and diabetes and efforts should be made to manage these metabolic complications aggressively to prevent ASCVD.

KW - acquired generalised lipodystrophy

KW - acquired partial lipodystrophy

KW - congenital generalised lipodystrophy

KW - familial partial lipodystrophy

KW - Lipodystrophy

KW - metreleptin

UR - http://www.scopus.com/inward/record.url?scp=85059146820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059146820&partnerID=8YFLogxK

U2 - 10.1016/j.pathol.2018.11.004

DO - 10.1016/j.pathol.2018.11.004

M3 - Article

JO - Pathology

JF - Pathology

SN - 0031-3025

ER -